Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | ATP4A | P20648 | 1/20 | 0.34 |
| ▸ | ATP4B | P51164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10943037 | 0.94 | ALDH1A1 (0.36) | ALDH1A1POLBMAPTBACE1SLC6A4 | |
| SCHEMBL19919045 | 0.93 | ALDH1A1 (0.38) | ALDH1A1POLBMAPTBACE1SLC6A4 | |
| SCHEMBL21339723 | 0.83 | SLC6A4 (0.32) | SLC6A4SLC6A2SLC6A3HTR2CMTNR1A | |
| SCHEMBL21339722 | 0.83 | SLC6A4 (0.32) | SLC6A4SLC6A2SLC6A3HTR2CMTNR1A | |
| SCHEMBL40067 | 0.81 | IDO1 (0.32) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL29398175 | 0.81 | IDO1 (0.32) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL28028910 | 0.79 | TDP1 (0.37) | ALDH1A1POLBMAPTSLC6A4 | |
| SCHEMBL394746 | 0.78 | ALDH1A1 (0.48) | ALDH1A1POLBMAPTBACE1SLC6A4 | |
| SCHEMBL28136200 | 0.78 | SKP2 (0.50) | ALDH1A1MAPTSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11117323 | 0.78 | ALDH1A1 (0.35) | ALDH1A1POLBMAPTBACE1ATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344018-B2 | Oxindolyl inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110135594-A1 | OXINDOLYL INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2011-06-09 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | ALDH1A1 957/4885POLB 718/4885MAPT 1634/4885 |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | ALDH1A1 2855/4885POLB 710/4885MAPT 2011/4885 |
| US-20110135594-A1 | OXINDOLYL INHIBITOR COMPOUNDS | HDAC1, HDAC8, HDAC11 | ALDH1A1 1388/4885POLB 428/4885MAPT 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.